clinical trial · NCT05934526
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
GB002, Inc.·phase3·completed·n = 390
Pulmonary Arterial HypertensionPlaceboSeralutinibGeneric Dry Powder Inhaler
brief summary
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
started
Dec 28, 2023
primary completion
Nov 27, 2025
completion
Dec 22, 2025
last updated
May 19, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol